Slovo úvodem

MUDr. Karel Grepl

Urolog. pro Praxi, 2008; 9(1): 3  

Erectile dysfunction - new preferences in treatment?

MUDr. Libor Zámečník FEBU

Urolog. pro Praxi, 2008; 9(1): 8-9  

The development of the first 5-phosphodiesterase inhibitor (sildenafil) and its introduction into routine clinical practice was a major breakthrough in the quality of treatment for such a tabooed issue as erectile dysfunction. Since then, the attitudes of both the society and the physicians towards this symptom have changed. Diagnosis and treatment of sexual dysfunctions have improved due to educational campaigns. Over time, however, other preparations have become available on the market. These not only differ in price (which, for some patients, may be a decisive factor in selection) but also in their pharmacological profile and effect. Any physician...

Hormonal regulations and possibilities of intervention in prostate cancer treatment

MUDr. Kamil Belej FEBU, MUDr. Ondřej Kaplan

Urolog. pro Praxi, 2008; 9(1): 10-15  

Since pivotal studies in 40´s of 20th century, hormonal therapy become the mainstay for the management of patiens with locally advanced and metastatic prostate cancer. In recent years, however, there has been an evolution towards increasing hormonal treatment of younger men with lower stage of disease or recurrent disease after definitive treatment. It is frequently used as a part of a multimodality approach.

The prevalence of lower urinary tract symptoms and overactivity bladder in women and men in common

MUDr. Miloš Broďák, MUDr. Lukáš Holub, MUDr. Josef Košina, et al

Urolog. pro Praxi, 2008; 9(1): 16-20  

The aim of this article is the evaluation of new data about the prevalence of lower urinary tract symptoms (LUTS) and an overactive bladder (OAB) in adult population. More recently there were published new results of a large prevalence studies. The prevalence of OAB in EU countries is about 16 % of the adult population, which means more than 22 million people older 18 than years. The results of studies pointed out, that 6 out of 10 people older 60 years have troubles from LUTS, and it is similar in women and men. It was proven, that OAB symptoms have a very negative impact on quality of life and seriously interferes with every day activities...

Testosterone supplementation therapy in testicular cancer patients

prof. MUDr. Dalibor Ondruš DrSc, RNDr. PhDr. Martina Ondrušová

Urolog. pro Praxi, 2008; 9(1): 21-23  

Improved survival of testicular cancer patients during the last years leads to rising of interest on the adverse disease consequences of whole the organism. Not only the tumor alone, but also its treatment (mainly radiotherapy or chemotherapy) may have impact on patient‘s hormonal status. The aim of this study was to assign the claim of hormonal profile examination into algorithm of follow-up not only in patients with bilateral disease, but also in patients with unilateral testicular tumor.

The cost of hormonal therapy for prostate cancer - Pharmacoeconomic aspects of treatment indications

Michaela Matoušková, Miroslav Hanuš

Urolog. pro Praxi, 2008; 9(1): 24-27  

Hormonal therapy for prostate cancer (CaP) is among the primary therapeutic modalities. Since indication principles have been well established, the only issues which remain controversial are the initiation of therapy and the type of therapy, i. e., early versus delayed and continuous versus intermittent. To date, no modality has been shown to have superior features supported by EBM (evidence based medicine). In addition to these medical drawbacks, one cannot ignore the high cost of the therapy resulting from both the price of medications and their long-term use. This is an issue addressed even in economically strong countries.

Komentář k práci Prieskum informovanosti laickej verejnosti o právnych a etických aspektoch transplantacií obličiek

doc. MUDr. Jan Báňa CSc

Urolog. pro Praxi, 2008; 9(1): 42  

Maligní neurilemom (schwannom) retroperitonea

MUDr. Miloslav Louda Ph.D, MUDr. Miloš Broďák, MUDr. Jaroslav Pacovský, et al

Urolog. pro Praxi, 2008; 9(1): 29-30  

Liposarkom semenného provazce

MUDr. Tomáš Vágner

Urolog. pro Praxi, 2008; 9(1): 31-32  

Predikční nomogramy u karcinomu prostaty

MUDr. Milan Král, doc. MUDr. Vladimír Študent Ph.D, MUDr. Martin Hrabec

Urolog. pro Praxi, 2008; 9(1): 33-35  

Program pracovní konference SAU 12. ledna 2008 Ski hotel, Nové Město na Moravě

Miroslav Hanuš

Urolog. pro Praxi, 2008; 9(1): 37-40  

Zpráva o workshopu Sekce urodynamiky a neurourologie České urologické společnosti ČLS JEP v rámci IV. setkání spinálních jednotek v České republice

MUDr. Libor Zámečník FEBU, MUDr. Jan Krhut Ph.D

Urolog. pro Praxi, 2008; 9(1): 41-42